Published: 2 March 2017

Recent Approvals of Medicines containing a New Active Ingredient

Prescriber Update 38(1): 15
March 2017

For period 16 October 2016 to 15 January 2017

Trade Name (active ingredient)* Dose form and strength Therapeutic area
Brimica Genuair (aclidinium/eformoterol) Powder for inhalation 340 mcg/12 mcg Chronic obstructive pulmonary disease (COPD)
Entresto 24/26 (sacubitril/valsartan) Film coated tablet 24.3 mg/25.7 mg Chronic heart failure
Epclusa (sofosbuvir/velpatasvir) Tablet 400 mg/100 mg Chronic hepatitis C virus infection
Genvoya (cobicistat/ elvitegravir/emtricitabine/ tenofovir) Tablet 150 mg/150 mg/200 mg/10 mg HIV-1 infection
Lynparza (olaparib) Capsule 50 mg Ovarian, fallopian tube or primary peritoneal cancer
Otezla (apremilast) Film coated tablet, titration pack 10mg, 20mg, 30mg Plaque psoriasis
Zepatier (elbasvir/grazoprevir) Film coated tablet 50 mg/100 mg Chronic hepatitis C virus infection (genotypes 1, 3, or 4)

* New active ingredient shown in bold type
The new active ingredient in Genvoya is tenofovir alafenamide fumarate (TAF), which replaces tenofovir disoproxil fumarate (TDF) in the related product Stribild.

The data sheets for currently marketed prescription medicines are published on the Medsafe website (